EU Awards 2,6 Million Euros for Patients with Chronic Cardiorenal Disease

To help patients manage their (potential) chronic heart and kidney disease, the European Commission has awarded 2,6 million euros to the CARRE project. A group of interdisciplinary researchers will compile personalised alerting, planning and educational services. This will empower patients, and both professionals and patients will be able to make shared informed decisions on the disease.

Cardiorenal syndrome is the condition characterised by simultaneous kidney and heart failure while the primarily failing organ may be either the heart or the kidney. Very often the dysfunction occurs when the failing organ precipitates the failure of the other.

Current studies estimate that 9-16% of the overall population is at risk or at the onset of chronic kidney disease, while chronic heart failure amounts to 1-2% of total healthcare costs and end-stage renal disease for more than 2% of total healthcare.

Challenging
Managing or even preventing this complex but common situation can be challenging: Comorbidities require care provision by different medical specialities while addressing a chronic patient trying to lead a normal life.

According to Robert Johnstone of the International Alliance of Patient Organizations there is a clear need for "patients to get up off their knees"!

Interlinked clinical information
To tackle this problem, the European Commission has decided to fund the CARRE project. This project will use internet aware sensors and other sources of medical information to provide dynamically interlinked clinical information personalized to the patient.

Patients and clinicians will be able to visualise, understand and interact with this linked knowledge via a set of decision support service in an all-inclusive and integrated approach the patient with (or at risk of) cardiorenal disease and comorbidities.

Partners
The CARRE consortium consists of 6 partners from 4 countries (Greece, United Kingdom, Lithuania and Poland) and is coordinated by the Democritus University of Thrace in Alexandroupoli, Greece.

The project is driven by two partners from the medical domain, namely the Democritus University of Thrace and the Vilnius University Hospital Santariškių Klinikos (LT), with a clear long experience in medical research in cardiorenal disease and comorbidities as well as with a long record of developing and deploying successful informatics interventions in the real healthcare setting.

The core semantic model and interlinking is performed by The Open University (UK) a leading expert in semantic technologies, while the University of Bedfordshire (UK) undertakes the work on visual analytics and cloud computing - both partners also contribute their long experience in semantic information extraction from unstructured data sources and web service oriented architectures.

Personal sensors
Kaunas University of Technology (LT), with a long proven innovation experience in personal sensors and sensor networks for cardiorenal disease tackles the integration of personalized sensor data. Finally, the Industrial Research Institute for Automation and Measurements (PL), an established partner in security and automation systems, brings in the required expertise on decision support systems and on systems security and data privacy.

The overall aim of the CARRE project is to show the potential of semantic interlinking of heterogeneous data to construct dynamic personalized models of complex comorbid medical conditions with disease progression pathways and comorbidity trajectories. Also, to show that visual analytics based on such models can support patient understanding of personal complex conditions (projected against ground knowledge and statistical views of similar patient population) and be the basis for shared decision support services for the management of comorbidities.

Freely available
All CARRE outcomes will be available as open source, protected under Creative Commons or GNU-GPL and other similar appropriate licensing schemes. CARRE project outcomes will thus be freely available for use and re-use by any interested party. Proof-of-concept will be shown via deployment and evaluation in two different healthcare settings.

The CARRE project is expected to reinforce the cardiorenal patients' understanding of the disease and the complex interdependencies of existing or projected comorbidities, supporting personalized treatment stratification, monitoring alerts, education and shared informed decision making.

Through these outcomes, CARRE strengthens the EU resolution to put the chronic patient at the center.

For further information, please visit:
http://www.carre-project.eu

About CARRE project
The CARRE project investigates information and communication technologies for empowering patients with comorbidities (multiple co-occurring medical conditions), or persons with increased risk of such conditions, especially in the case of chronic cardiac and renal disease patients. The CARRE project has received a 3-year EC funding from the European Community 7th Framework Programme FP7-ICT-2013 work programme under grant agreement no. 611140.

Most Popular Now

Philips and Medtronic Advocacy Partnersh…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Medtronic Neurovascular, a leading innovator in neurovascular therapies, today announced a strategic advocacy partnership. Delivering timely stroke...

Wearable Cameras Allow AI to Detect Medi…

A team of researchers says it has developed the first wearable camera system that, with the help of artificial intelligence (AI), detects potential errors in medication delivery. In a test whose...

New AI Tool Predicts Protein-Protein Int…

Scientists from Cleveland Clinic and Cornell University have designed a publicly-available software and web database to break down barriers to identifying key protein-protein interactions to treat with medication. The computational tool...

AI for Real-Rime, Patient-Focused Insigh…

A picture may be worth a thousand words, but still... they both have a lot of work to do to catch up to BiomedGPT. Covered recently in the prestigious journal Nature...

New Research Shows Promise and Limitatio…

Published in JAMA Network Open, a collaborative team of researchers from the University of Minnesota Medical School, Stanford University, Beth Israel Deaconess Medical Center and the University of Virginia studied...

G-Cloud 14 Makes it Easier for NHS to Bu…

NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of...

Start-Ups will Once Again Have a Starrin…

11 - 14 November 2024, Düsseldorf, Germany. The finalists in the 16th Healthcare Innovation World Cup and the 13th MEDICA START-UP COMPETITION have advanced from around 550 candidates based in 62...

Hampshire Emergency Departments Digitise…

Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of...

MEDICA HEALTH IT FORUM: Success in Maste…

11 - 14 November 2024, Düsseldorf, Germany. How can innovations help to master the great challenges and demands with which healthcare is confronted across international borders? This central question will be...

A "Chemical ChatGPT" for New M…

Researchers from the University of Bonn have trained an AI process to predict potential active ingredients with special properties. Therefore, they derived a chemical language model - a kind of...

Siemens Healthineers co-leads EU Project…

Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total...

MEDICA and COMPAMED 2024: Shining a Ligh…

11 - 14 November 2024, Düsseldorf, Germany. Christian Grosser, Director Health & Medical Technologies, is looking forward to events getting under way: "From next Monday to Thursday, we will once again...